Uganda Sickle Surveillance Study (US-3) - Trial NCT06301893
Access comprehensive clinical trial information for NCT06301893 through Pure Global AI's free database. This phase not specified trial is sponsored by Children's Hospital Medical Center, Cincinnati and is currently Recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 1000000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Children's Hospital Medical Center, Cincinnati
Timeline & Enrollment
N/A
Sep 07, 2013
Dec 31, 2032
Primary Outcome
Incidence of HbSS and HbA
Summary
It is estimated that over 250,000 babies are born with sickle cell disease (SCD) annually in
 sub-Saharan Africa, and only 10% - 50% of them survive beyond five years of age. Data
 describing the magnitude of the sickle cell problem are lacking in most African countries.
 The available data on prevalence were mainly from older studies and small numbers of
 hospitalized patients. In Uganda, approximately 25,000 children are born with SCD but 70-80%
 die before their 5th birthday. Lehmann and Raper found 'sicklaemia' prevalence of 0.8% and
 45% in the Sebei and Bambaa ethnic groups, respectively. A recent study found a SCT and SCD
 prevalence of 3% - 19% and 0% - 3%, respectively but this study addressed only 5 of Uganda's
 111 districts and used a small convenience sample of children aged 6 - 60 months. The
 objective of this study is to determine the prevalence and map out the burden of SCT and SCD
 in Uganda.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06301893
Non-Device Trial